October 09- 10, 2019
Madrid, Spain
On behalf of the organizing Committee, I would like to welcome you to 2nd World Congress on COPD, Asthma and Lung health (Lung health 2019) conference. It is our pleasure to serve this kind of an international event and is thankful to you for being part of this initiative. The conference program will also include various themes and topics related to Lung Health and Pulmonology and Respiratory Diseases.
We are all looking forward to a great Conference, with excellent keynotes and tutorials, interesting sessions, and a unique social program. I’d like to thank each of you for attending our Lung health 2019 conference and bringing your expertise to our gathering. You have the vision, the knowledge, and the experience to help us pave our way into the future. Throughout this conference, I ask you to stay engaged, keep us proactive and help us shape the future of Lung health profession.
I wish you all a very successful Conference and thank you for being a part of this event.
By Dr. Ekram Wassim Abd El-Wahab
Alexandria University, Egypt
About Conference
Pulsus Group invites all the participants from across the World to attend "2nd World Congress on COPD, Asthma and Lung Health" during October 09-10, 2019 at Madrid, Spain. This includes proficient keynote presentations, verbal speeches, productive poster presentations and exhibitions.
Pulsus Group performs 1000+ Global events annually, is delighted to welcome all the interested and enthusiastic participants across the globe to the prestigious Conference on “2nd World Congress on COPD, Asthma and Lung Health” during October 09-10, 2019 at Madrid, Spain. Lung Health 2019 highlights the theme “Frontiers in Lung Health Research”.
Pulmonologists face a wide variety of challenges: Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe progressive lung diseases including Asthma, emphysema, chronic bronchitis, and some forms of bronchiectasis. The lack of comprehensive information about the disease people with COPD typically ranges from 40% to 70%, depends on disease severity, while the 2-year mortality rate for people with severe COPD is about 50%. Survival rates for people with severe COPD are, in fact, worse than those for people with many common cancers. The COPD Foundation was established to undertake initiatives that result in expanded services for COPD and to improve the lives of individuals affected by COPD. The Foundation’s activities focus on achieving these results through research, education and advocacy programs that will lead to prevention and a cure for this disease.
Designation Statement
Pulsus Group is a Medical publisher that binds to stringent peer-review procedure with a view to set an example in enlightening standard medical research with integrity and attentiveness, established in 1984 with many offices in Singapore, Ontario, Canada and India. Pulsus Group takes dignity in assimilating the endorsements of prestigious associations and societies like Canadian Medical Societies, International Medical Societies. As a fervent supporter of medical publishing to expand its open access publishing through its 50+ journals in association with 20+ International medical and scientific societies. It publishes an extensive range of Medical Journals that focus on medical specializations like Cardiology, integrative medicine, surgery and reproductive medicine. Pulsus Group is closely associated with globally renowned academic and research societies like Canadian Transplant Society, Canadian Society of Plastic Surgeons, Canadian Society for Aesthetic Plastic Surgery, Group pours Canada, Canadian Society for Surgery of the Hand.
Pulsus Group performs 1000+ Global events annually, is delighted to welcome all the interested and enthusiastic participants across the globe to the prestigious Conference on “Lung Health 2019” going to held during October 07-08, 2019 at Madrid, Spain.Lung Health 2019 highlights the theme “Frontiers in Lung Health Research”.
Who should attend ?
• Pulmonology Students, Scientists and Professors
• Pulmonology Researchers
• Pulmonology Faculty
• Healthcare Students, Scientists and professors
• Health Care Researchers
• Healthcare Faculty and Equipment Management
• Medical Colleges
• Healthcare Associations and Societies
• Business Entrepreneurs
Why to Attend ?
The Lung Health 2019 will provide a good opportunity to learn more clinical information and also it will enlighten the world with recent advances in COPD, Asthma and other Lung Diseases and Pulmonology research and inculcate new ideas about healthy breathing. Moreover, this COPD Conferences provides the participants with a great networking with peers. Internationally prominent speakers, the novel techniques, and the modern updates in the lung research fields are the unique attributes of this conference. COPD Conferences, symposiums and Workshops provide a dedicated forum for the advancement, execution and exchange of information about Pulmonology and Lung Health.
Scope and Importance
Pneumonic health has a specific enthusiasm for the effect changes in respiratory care and the mindfulness is expanding each year, and subsequently, Lung Health 2019 energizes entries from scientists situated in USA, Europe and Asian nations.
The test of the field is to assess flow promising intercessions thoroughly, address rising issues, for example, incorporating consistently expanding research discoveries and create inventive dispersal and correspondence procedures.
The diary welcomes entries on exploring in COPD, Asthma, tuberculosis, including emphysema, aspiratory recovery, cystic fibrosis, various pulmonary disease and themes identified with respiratory wellbeing.
Lung Health 2019 provides a stage that encourages creators to impart their insight into a more extensive group of onlookers and supports a quick procedure for entries bringing about excellent distributions. We additionally mean to contribute towards lessening the disparity in distributions from low-and centre wage nations. Our group of onlookers is worldwide, and we mean to share explore brings about COPD from all parts of the world.
Session 01: Lung Disease
Lung diseases disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Altogether, lung diseases accounted for more than 3 million people die each year from COPD and 235 million people suffer from asthma, a common disease among children.
Related Conferences:
Chest Annual meeting 2019 October 19-23, 2019, USA | International Conference on COPD and Lungs March 11-12, 2019 Singapore | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal | Infectious Diseases Conferences September 27-29, 2018 Rome, Italy | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019.
Related Societies:
European Pulmonary Hypertension Association (EPHA) | European Association for Bronchology and Interventional Pulmonology (EABIP) | American Association for Respiratory Care (AARC) | European Society of Federasma and Allergies(ESFA) | Japanese Respiratory Society (JRC).
Session 02: Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus production and wheezing. It's caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. Emphysema and chronic bronchitis are the two most common conditions that contribute to COPD. The inflamed bronchial tubes produce a lot of mucus. This leads to coughing and difficulty breathing. It's characterized by a daily cough and mucus production.
Related Conference:
International Conference on COPD and Lungs March 11-12, 2019 Singapore | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 |
Related Societies:
Peruvian Society of Pneumology; The Primary Care Respiratory Society UK(PCRS-UK) | Romanian Society of Pneumology; Thoracic Society of Australia and New Zealand(TSANZ) | European Association for Bronchology and Interventional Pulmonology; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF)
Session 03: Asthma and COPD
Asthma is one of the chronic disease involving the airway in the lungs. This airway is called bronchial tubes, allow air to come in and out of the lungs. In this asthma your airway gets, and it will produce extra mucus. So that it can make breathing difficult and trigger coughing, wheezing and shortness of breath. It can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack. Asthma can't be cured, but its symptoms can be controlled. Because asthma often changes over time, it's important that we need to track our signs and symptoms and adjust treatment as needed. Asthma causes difficulty in breathing that often results from an allergic reaction. When it comes to COPD both are chronic inflammatory diseases that include the little airway routes and cause airflow impediment, both from communications and both are typically characterized by mucus and bronchoconstriction.
Related Conference:
International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Conference on COPD and Lungs March 11-12, 2019 Singapore | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
The Primary Care Respiratory Society UK(PCRS-UK) | Romanian Society of Pneumology | European Association for Bronchology and Interventional Pulmonology |Chinese Association of Chest Physicians(CACP) | Indian Chest Society(ICS).
Session 04: Lung cancer
Lung cancer is a type of cancer that begins in the lungs and the uncontrolled growth of abnormal cells in one or both lungs. Your lungs are two spongy organs in your chest that take in oxygen when you inhale and release carbon dioxide when you exhale. Once the tumours have become larger and increased in number, they make it difficult for the lungs to provide oxygen to the bloodstream. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. The risk of lung cancer increases with the length of time and the number of cigarettes you've smoked. These cells usually line the air passages and divide rapidly to form tumours.
Related Conference:
European Lung Cancer Congress 2019, April 10 - 13 2019, Geneva, Switzerland | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Conference on COPD and Lungs March 11-12, 2019 Singapore | Austrian Society Of Pneumology Annual Meeting 2019 (OGP 2019) October 10-12 2019,Wien.
Related Societies:
Romanian Society of Pneumology; Thoracic Society of Australia and New Zealand(TSANZ) | European Association for Bronchology and Interventional Pulmonology | European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF) | Chinese Association of Chest Physicians(CACP) | Indian Chest Society(ICS).
Session 05: Tuberculosis
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the disease. One of the most commonly used vaccine for Tuberculosis infected patients especially for the infants is bacillus calmette guerin(BCG).
Related Conference:
Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Conference on COPD and Lungs March 11-12, 2019 Singapore | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
European Pulmonary Hypertension Association(PHA) | Italian Society for Infant Respiratory Diseases; Brazilian Society of Pneumology and Tisiology | Argentine Association of Respiratory Medicine(AAMR) | Saudi Thoracic Society(STS)
Session 06: Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring fibrosis of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen. IPF is a form of interstitial lung disease, primarily involving the interstitial the tissue and space around the air sacs of the lungs, and not directly affecting the airways or blood vessels. There are many other kinds of interstitial lung disease that can also cause inflammation and/or fibrosis, and these are treated differently.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Conference on COPD and Lungs March 11-12, 2019 Singapore | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF) | Croation Respiratory Society | Peruvian Society of Pneumology | Chinese Thoracic Society(CTS) | Chinese Association of Chest Physicians; Indian Chest Society(ICS).
Session 07: Cystic Fibrosis
Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. These secreted fluids are normally thin and slippery. But in people with cystic fibrosis, a defective gene causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Conference on COPD and Lungs March 11-12, 2019 Singapore | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
European Association for Bronchology and Interventional Pulmonology | European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF) | Chinese Association of Chest Physicians(CACP) | Indian Chest Society(ICS) | Association for Respiratory Technology and Physiology(ARTP) | British Lung Foundation(BLF).
Session 08: Stages of Asthma
Stage-1 or intermittent asthma: This group of children has symptoms no more than two times a week, do not have problems in-between flare-ups, and only have short flare-ups from a few hours to a few days. Night-time symptoms occur less than two times a month.
Stage 2 or mild persistent: This group of children has symptoms more than two times a week, but not daily, and may have activity levels affected by the flare-ups. Night-time symptoms occur greater than two times a month, but no more than once per week.
Stage 3 or moderate persistent: This group of children has symptoms every day, use their rescue medication every day and may have activity levels affected by the flare-ups. Night-time symptoms occur greater than one time a week.
Stage 4 or severe persistent: This group of children has symptoms multiple times per day, have a decrease in their physical activity and have frequent flare-ups. Night-time symptoms occur frequently.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Conference on COPD and Lungs March 11-12, 2019 Singapore | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
Cambodian Pulmonology Association(CPA) | Australian & New Zealand Society of Respiratory Science | Chinese Society of Respiratory Diseases | Global Initiative for Asthma | Ho Chi Minh City Respiratory Society | Hong Kong Lung Foundation | Hong Kong & Macau Chapter of the American College of Chest Physicians HK & M (CHEST) | Hong Kong Tuberculosis, Chest & Heart Disease Association.
Session 09: Asthma Immunopathology
Bronchial asthma is a resistant interceded issue described by reversible aviation route irritation, mucous discharge, and a variable stream of air deterring with aviation route hyperresponsiveness. Allergen presentation prompts the initiation of different cells of the framework, of those dendritic cells and Th2 lymphocytes are of principal significance. Even though the epithelium was at first considered to work independently as a physical boundary, it is as of now detectable that it assumes a focal part in the Th2-cell refinement process because of its possibility to initiate dendritic cells. Pole cells and eosinophil were at first accepted to assume a key part in driving the aviation route irritation related to asthma, new information infer that T partner cells are basic. It has been demonstrated that hypersensitive asthma is related with expanded TH2 cytokine generation that causes initiation of eosinophils and T-cells and creation of chemokine by aspiratory fibroblasts.
Related Conference:
International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Conference on COPD and Lungs March 11-12, 2019 Singapore |Malaysian Thoracic Society Annual Congress 2019 (MTS 2019) July 18-19 2019 ,Malaysia.
Related Societies:
Philippine College of Chest Physicians(PCCP) | Korean Academy of Tuberculosis and Respiratory Diseases(KATRD) | European Society of Federasma and Allergies | European Pulmonary Hypertension Association(PHA) | International Collaboration of Sleep Apnea Cardiovascular Trialists |
Session 10: COPD Pathogenesis
Pathogenesis of chronic obstructive pulmonary disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Basically, it has characterized, inflammation in the peripheral air spaces in different stages of disease severity. The first is a Protease-Antiprotease imbalance, which has been linked to the pathogenesis of emphysema. The second process, oxidative stress, has a role in many of the pathogenic processes of chronic obstructive pulmonary disease and may be one mechanism that enhances the inflammatory response.
Related Conference:
Malaysian Association for Bronchology and Interventional Pulmonology Annual Scientific Meeting 2019 (MABIP 2019) October 18-20 2019,Kuching | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Conference on COPD and Lungs March 11-12, 2019 Singapore |
Related Societies:
European Pulmonary Hypertension Association(PHA) | Italian Society for Infant Respiratory Diseases; Brazilian Society of Pneumology and Tisiology | Argentine Association of Respiratory Medicine(AAMR) | Saudi Thoracic Society(STS)
Session 11: Epidemiology of COPD
Chronic obstructive pulmonary disease (COPD) is responsible for early mortality, high death rates and significant cost to health systems. Active smoking remains the main risk factor, but other factors are becoming better known, such as occupational factors, infections and the role of air pollution. Prevalence of COPD varies according to the country, age and sex. This disease is also associated with significant comorbidities. COPD is a disorder that includes various phenotype, the continuum of which remains under debate. The major challenge in the coming years will be to prevent the onset of smoking along with early detection of the disease in the general population. This may represent deterioration in the patient's premorbid condition such that hypoxemia worsens and hypercapnia develops during a relatively trivial respiratory tract infection, which may be viral or bacteria.
Related Conference:
International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | Medical Specialty 14th Annual New York Lung Cancer Symposium 2019 November 9 2019,Newyork.
Related Societies:
Philippine College of Chest Physicians(PCCP) | Korean Academy of Tuberculosis and Respiratory Diseases(KATRD) | European Society of Federasma and Allergies | European Pulmonary Hypertension Association(PHA) | Society of Critical Care Medicine | Turkish Respiratory Society
Session 12:Cardiovascular Diseases and COPD
Numerous cohort studies have demonstrated an increased risk of cardiovascular-related mortality in patients with COPD. Interestingly, this association is often seen in mild and moderate COPD. It is both disappointing and depressing that both the management of cardiovascular disease and the assessment of risk in patients with COPD is repeatedly suboptimal. The amino acids desmosine and isodesmosine are involved in elastin cross-linking, have utility as a measure of elastin breakdown, and may have value in determining both risk of cardiovascular disease and a link to a possible causal mechanism. The detection of increased arterial stiffness in patients with COPD furthers leads to the understanding of the possible mechanism for cardiovascular disease in COPD.
Related Conferences:
World Cardiology Conference, September 17-18, 2018, Hong Kong; Global Experts meeting on Chronic Diseases, November 14-15, 2018 Tokyo, Japan; International Conference on Obesity and Chronic Diseases, October 15-16, 2018, Dubai, UAE; International Conference on Epidemiology & Public Health, September 17-19, 2018, Rome, Italy; International Conference on Pre-Hypertension, Hypertension and Cardio Metabolic Syndrome, October 01-04, 2018, Kuala Lumpur, Malaysia.
Related Societies:
European Association for the Study of the Liver | European Academy of Allergy and Clinical Immunology | The American Heart Association | Heart Failure Society of America | Alliance of Cardiovascular Professionals | Society for Neuroscience
Session 13: Respiratory Failure and COPD Complications
Patients who struggle with advanced COPD and acute or chronic respiratory failure are at high risk of death. Beyond pharmacological treatment, supplemental oxygen and mechanical ventilation are major treatment options. If your lungs fail to do their job passing oxygen into your bloodstream and removing carbon dioxide. It can be a complication of chronic obstructive pulmonary disease (COPD). In respiratory failure, the gas exchange doesn't work the way it's supposed to work, and the cells in your body start to suffer from a lack of oxygen, too much carbon dioxide, or both. Too much carbon dioxide can disrupt the acid-base balance in the body, which in itself can lead to respiratory failure.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Conference on COPD and Lungs March 11-12, 2019 Singapore | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
European Association for Bronchology and Interventional Pulmonology (EABIP) | American Association for Respiratory Care (AARC) | European Society of Federasma and Allergies(ESFA) | Japanese Respiratory Society (JRC) | Thoracic Society of Australia and New Zealand(TSANZ) | South African Thoracic Society
Session 14: Pathophysiology of COPD
Basically, the pathophysiology of COPD is rapidly unveiling. There will be some physiological change which eventually impacts the quality of life and survival in the natural progress of COPD when The pathological consequences of the COPD inflammation induce a series of physiological changes. Fibrotic remodelling of the airways results in fixed airway narrowing causing increased airway resistance which does not fully revert even with bronchodilators. Emphysema also reduces lung elastic recoil pressure which leads to a reduced driving pressure for expiratory flow through narrowed and poorly supported airways in which airflow resistance is significantly increased.
Related Conference:
International Conference on COPD and Lungs March 11-12, 2019 Singapore | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
Association for Respiratory Technology and Physiology(ARTP) | British Lung Foundation(BLF) | European Society of Federasma and Allergies(EU-SFA) | American Lung Association | Thoracic Society of Australia and New Zealand(TSANZ) | American Association for Respiratory Care (AARC) | European Society of Federasma and Allergies(ESFA).
Session 15: Pulmonary Diseases-Treatment and Therapies
Treatment is depending upon the type of disease and stages. Either it will be treated in the surgical or non-surgical method, when it comes to the surgical process some of the treatments are lung transplant, Lung volume reduction surgery and Bullectomy, another type is known a non-surgical process here, Airway clearance therapy, Pulmonary Rehabilitation, Vaccines, and antibiotics.
Related Conference:
International Conference on COPD and Lungs March 11-12, 2019 Singapore | American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF) | Croation Respiratory Society | Peruvian Society of Pneumology | Chinese Thoracic Society(CTS) | Chinese Association of Chest Physicians; Indian Chest Society(ICS).World Association of Bronchology and Interventional Pulmonology | Singapore Thoracic Society
Session 16: Self-Management and Prevention of COPD
Patients with Chronic Obstructive Pulmonary Disease have to acquire and the skills they need to carry out disease, Self-management in chronic obstructive pulmonary disease, centring on an action plan for the exacerbation and enhanced communication between the patient and healthcare providers, make good clinical sense. only two demonstrated reductions in health care utilization and one had to be discontinued prematurely because of increased mortality. Breathing techniques that can help you get the air you need without working so hard to breathe, Our primary objective was to assess the long-term effects of two different modes of COPD disease management comprehensive self-management and routine monitoring on quality of life in COPD patients in general practice. As secondary objectives, we assessed the effects on frequency and patients’ management of exacerbations and on self-efficacy. A systematic review of self-management in COPD concluded that it reduces hospital admissions and has no detrimental effects.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Conference on COPD and Lungs March 11-12, 2019 Singapore | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
Peruvian Society of Pneumology; The Primary Care Respiratory Society UK(PCRS-UK) | Romanian Society of Pneumology | Thoracic Society of Australia and New Zealand(TSANZ) | European Association for Bronchology and Interventional Pulmonology | European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF).Taiwan Society of Pulmonary & Critical Care Medicine | Turkish Thoracic Society
Session 17: Advanced Respiratory Disease Treatment
Nowadays patients with Respiratory diseases use various devices, which help the removal of mucus from the Airways and the improvement of pulmonary function.Pulmonary Rehabilitation helps in recovering the normal lung expiration and inspiration through trainings and exercises. Other Advanced treatment methods are Bullectomy and Bronchoscopic lung volume surgery where the idea is to provide a free air pathway without any resistance. Nowadays devices seem to increase patients' compliance with daily treatment, because they present many benefits, as an independent application, full control of therapy and easy use.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Conference on COPD and Lungs March 11-12, 2019 Singapore | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
European Association for Bronchology and Interventional Pulmonology | European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF) | Chinese Association of Chest Physicians(CACP) | Indian Chest Society(ICS) | Association for Respiratory Technology and Physiology(ARTP) | British Lung Foundation(BLF).
Session 18: Paediatric Pulmonary Critical care and Sleep
The Division of Paediatric Pulmonary and Sleep Medicine provides comprehensive care to infants, children and adults with a full spectrum of respiratory disorders. Care is guided in all age groups by the routine measurements of lung function. This department also provides the teaching and training in paediatric Pulmonology for diagnosing and treating the various disorders. mostly various pulmonary disorders are treated with the help of ventilation machines and medications.
Related Conference:
American Academy of Allergy, Asthma & Immunology Annual Meeting February 22-26, 2019, San Francisco | International Workshop on Lung Health Asthma and COPD 2019, January 17-19, 2019, France | Canadian Respiratory Conference, April 11-13, 2019, The Westin Ottawa | Pulmonary and Critical Care Medicine, Boston, April 28, 2019 - May 1, 2019 | Annual Chest Disease Conference 2019, Sunriver, February 14-17, 2019 | International Conference on COPD and Lungs March 11-12, 2019 Singapore | European Academy of Allergy & Clinical Immunology 01-05 June 2019 Lisbon, Portugal.
Related Societies:
Peruvian Society of Pneumology; The Primary Care Respiratory Society UK(PCRS-UK) | Romanian Society of Pneumology | Thoracic Society of Australia and New Zealand(TSANZ) | European Association for Bronchology and Interventional Pulmonology | European Idiopathic Pulmonary Fibrosis & Related Disorders Federation(EU-IPFF).
Session 19:Diagnosis for Pulmonary Disorders
The most traditional method for diagnosing the pulmonary disorders is with the usage of the spirometer which generally provides measurement about the lung capacity and also about the inhalation and exhalation of air. By using spirometer it is also possible to tract the progression of the disease such as COPD and also early detection of the disease.
Related Conference:
South African Thoracic Society, Allergy Society of South Africa and Chest Wall Interest Group Joint Meeting 2019 (SATS ALLSa CWIG 2019) June 25-28 2019,Pretoria | European Ntm & Bronchiectasis Workshop 2019 July 6-8 2019,Vienna | 1st Adult Cystic Fibrosis International Workshop 2019 July 5-6 2019, Milan | IASLC 2019 North America Conference on Lung Cancer 2019 (NACLC 2019) October 10-12 2019, Chicago .
Related Societies:
Italian Society for Infant Respiratory Diseases | Brazilian Society of Pneumology and Tisiology | Argentine Association of Respiratory Medicine(AAMR) | Saudi Thoracic Society(STS) | Association for Respiratory Technology and Physiology(ARTP) | British Lung Foundation(BLF) | Kyrgyz Thoracic Society | Mongolian Respiratory Society | U.S. National Lung Health Education Programme | Philippine College of Chest Physicians
Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, are responsible for a substantial health and financial burden each year. 6.7% of all deaths were due to chronic respiratory diseases, which were the fifth leading cause of death. Geographically precise annual estimates of chronic respiratory disease mortality by type would allow a more complete understanding of regional variation in chronic respiratory disease mortality rates and may be useful for clinicians and policymakers interested in reducing geographic disparities and the health and financial burdens of chronic respiratory diseases overall.It is also stated that about 60% of the available respiratory devices in the market are most commonly used for the COPD patient.
A higher proportion of men than women in the EU-28 died from diseases of the respiratory system (8.3 % compared with 7.2 %). This pattern was repeated across most of the EU Member States and was most pronounced in Estonia where the difference between the sexes was 2.7 percentage points, Spain (2.6 points), Lithuania (2.3 points), Romania (2.1 points), Latvia and Croatia (both 2.0 points). By contrast, a higher proportion of deaths among women (rather than men) were attributed to diseases of the respiratory system in Denmark, Ireland, Greece, the United Kingdom and Luxembourg; this was also the case in Liechtenstein.
Pneumonic health has a specific enthusiasm for the effect changes in respiratory care and the mindfulness is expanding each year, and subsequently, Lung Health 2019 energizes entries from scientists situated in USA, Europe and Asian nations. The diary welcomes entries on exploring in COPD, including emphysema, tuberculosis, asthma, aspiratory recovery, cystic fibrosis, lung disease and themes identified with respiratory wellbeing.
Lung Health 2019 provides a stage that encourages creators to impart their insight into a more extensive group of onlookers and supports a quick procedure for entries bringing about excellent distributions. We additionally mean to contribute towards lessening the disparity in distributions from low-and centre wage nations. Our group of onlookers is worldwide, and we mean to share explore brings about COPD from all parts of the world.
List of Top Hospitals for Pulmonary Disease Treatment
List of Top Universities Associated with COPD Research
List of Leading Companies related to the production of Pulmonary equipment
Figure 1: Death Rate
Lung Foundation and Association:
A Breath of Hope Lung Foundation
Alabama Society for Respiratory Care
Albany Med Communication
Alpha-1 Association
American Association for Cardiovascular and Pulmonary Rehabilitation (AACVPR)
American Association for Respiratory Care
American Association for Respiratory Care (AARC)
American College of Chest Physicians
American Lung Association's National Office
American Public Health Association
American Respiratory Care Foundation
American Thoracic Society
Arthritis Foundation
Asian Pacific Society of Respirology
Asociación Latinoamericana del Tórax Latin American Thoracic Association
Associazione Italiana Pneumologi Ospedalieri (AIPO)
Asthma and Respiratory Foundation
ATS Foundation
Aultman Health Foundation
Australian & New Zealand Society of Respiratory Science
Bangladesh Lung Foundation
Belgian Thoracic Society
Better Breathing Foundation
BMC Pulmonary Medicine
Breath the Lung Association
Breathe California Golden Gate
BREATHE California of Los Angeles
British Lung Foundation
British Thoracic Society
California Thoracic Society
Cambridge Health Alliance
Canadian Pulmonary Fibrosis Foundation
Carers Victoria
Center for Disease Control and Prevention
Center for Disease Control and Prevention
Chest Foundation
Christiana Care
Connecticut Society for Respiratory Care
COPD Association
COPD Canada
COPD Foundation
COPD International
COPD News Today
COPD Support Ireland
Cystic Fibrosis Foundation
European Academy of Allergy & Clinical Immunology
European Association for Bronchology and Interventional Pulmonology
European COPD Coalition
European Idiopathic Pulmonary Fibrosis & Related Disorders Federation
European Lung White Book
European Pulmonary Hypertension Association
European Respiratory Society
Finnish Lung Health Association
Georgia Society for Respiratory Care
Georgian Respiratory Association
Global Initiative for Asthma
Global Initiative for Chronic Obstructive Lung Disease
Gundersen Health System
Hawaii COPD Coalition
Heart Lung Foundation
Hellenic Thoracic Society
HHV-6 FOUNDATION
Hispanic-American Allergy Asthma and Immunology Association
Ho Chi Minh City Respiratory Society
Hong Kong & Macau Chapter of the American College of Chest Physicians
Hong Kong Lung Foundation
Hong Kong Thoracic Society
Hong Kong Tuberculosis, Chest & Heart Disease Association
Huma Lung Foundation
Hunterdon Healthcare
Huntington’s Disease News
Illinois Heart & Lung Foundation
Indian Chest Society
Indian Society for Study of Lung Cancer
Indonesian Society of Respirology
International Association for the Study of Lung Cancer
International Council for Respiratory medicine
International Primary Care Respiratory Group
International Society for Heart and Lung Transplantation
International Union Against Tuberculosis & Lung Disease
Iowa Society for Respiratory Care
Irish Thoracic Society
Japan Lung Cancer Society
Japanese Respiratory Society
Journal Respiratory Care Company
JPS Health Network
Korean Academy of Tuberculosis and Respiratory Diseases
Lithuanian Pulmonologist Society
Lung Cancer Alliance
lung cancer research foundation
Lung Care Foundation
Lung Foundation Australia
Lung Foundation Netherlands
Lung Foundation NZ
Lung Transplant Foundation
Macedonian Respiratory Society
Malaysian Thoracic Society
Marfan Foundation
Memphis Lung Physicians Foundation
Mission Health
Montana Society for Respiratory Care
Montreal Chest Institute Foundation
National Emphysema Foundation
National Fabry Disease Foundation
National Heart, Lung and Blood Institute Information Center
National Hospice and Palliative Care Organization
National Jewish Medical & Research Center Lung-Line
National Lung Health Education Program
National Sleep Foundation
Netherlands Respiratory Society
New York State Society for Respiratory Care
NORML Foundation
Northwell Health
Primary Care Respiratory Medicine
Ohio Society for Respiratory Care
Oklahoma Thoracic Society
Oregon Society for Respiratory Care
Palo Alto Medical Foundation
PAN Africa Thoracic Society
Pennsylvania Society for Respiratory Care
Philippine College of Chest Physicians
Pulmonary Alveolar Proteinosis Foundation
Pulmonary Fibrosis Foundation
Pulmonary Fibrosis Trust
Pulmonary Hypertension Association
Pulmonologists Society Republic of Srpska
Rady Children's Hospital-San Diego
Respiratory Health Association
Respiratory Health Association - lung Chicago
Respiratory Research
Respiratory Society of French Language (SPLF)
Saint Agnes Medical College
Saudi Thoracic Society
Saudi thoracic Society
Scleroderma Foundation
Second Wind Lung Transplant Association, Inc
Singapore Respiratory Specialists
Singapore Thoracic Society
Society of Critical Care Medicine
Society of Hospital Medicine
South African Thoracic Society
Taiwan Society of Pulmonary & Critical Care Medicine
Tennessee Society for Respiratory Care
The Breathing Association
The Chartered Society of Physiotherapy
The European Lung Foundation
The Irish Thoracic Society
The Kansas Respiratory Care Society
The Korean Academy of Tuberculosis and Respiratory Diseases
The LAM Foundation
The Lung Association – Ontario
The Lung Foundation of Malaysia
The National Emphysema Foundation
The Primary Care Respiratory Society UK
The Primary Care Respiratory Society UK
The Society for Post-Acute and Long-Term Care Medicine
The Society of Thoracic Surgeons
The Thoracic Society of Australia and New Zealand
Thoracic Society of Australia and New Zealand
Thoracic Society of Thailand
Thorax BMJ Journals
Turkish Respiratory Society
Turkish Thoracic Society
U.S. National Heart, Lung & Blood Institute
U.S. National Institute of Allergy & Infectious Diseases
U.S. National Institute of Health
US COPD Coalition
Utah Society for Respiratory Care
Vietnam Respiratory Society
WAO World Allergy Organization
WellStar Health System
Welsh Thoracic Society
World Allergy Organization
World Association of Bronchology and Interventional Pulmonology
World Health Organization
World Lung Foundation in Switzerland
World Lung Foundation-South Asia
Lung Disease Overview:
When you think of lung disease, you may think of lung cancer, but there are actually many different types. Altogether, lung diseases accounted for more than 3 million people die each year from COPD and 90% of deaths occur in low-income and middle-income countries. 235 million people suffer from asthma, a common disease among children according to the World Health Organization.
These types of lung diseases may affect your airways, lung tissues, or circulation of blood in and out of your lungs. Here are the most common types, their causes and risk factors, and potential symptoms that may signal the need for medical attention.
Lung Diseases Affecting the Airways
1. Asthma:
Asthma is one of the most common types of chronic lung disease. When triggered, your lungs become swollen and narrow, making it harder to breathe.
Symptoms include:
· Wheezing
· Being unable to take in enough air
· Coughing
· Feeling tightness in your chest
If you experience these symptoms, it’s important to see a doctor right away. Triggers may include allergens, dust, pollution, stress, and exercise.
Asthma usually starts in childhood, though it can begin later. It can’t be cured, but medications can help control symptoms. The disease affects about 26 million Americans and tends to run in families.
Most people with asthma can manage it fine and enjoy full and healthy lives. Without treatment, though, the disease can be deadly. Doctors don’t know yet why some people get asthma and others don’t. But they believe that genetics play a large role. If someone in your family has it, your risk goes up.
2. Chronic Obstructive Pulmonary Disease:
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus production and wheezing. It's caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. Emphysema and chronic bronchitis are the two most common conditions that contribute to COPD.
Symptoms can get progressively worse and harder to ignore. As the lungs become more damaged, you may experience:
· shortness of breath, after even mild exercise such as walking up a flight of stairs
· wheezing, or noisy breathing
· chest tightness
· Chronic cough, with or without mucus
· need to clear mucus from your lungs every day
· frequent colds, flu, or other respiratory infections
What Causes COPD?
The single greatest reason for COPD is cigarette smoking. Around 90 percent of individuals who have COPD are smokers or previous smokers. Among smokers, 20 to 30 percent create COPD. Numerous others create lung conditions or have diminished lung work. The vast majority with COPD is more than 40 years of age and have at any rate some history of smoking. The more you smoke, the more prominent your danger of COPD is. Notwithstanding tobacco smoke, stogie smoke, pipe smoke, and used smoke can cause COPD. Your danger of COPD is much more prominent if you have asthma and smoke.
Bronchitis is an inflammation of the lining of the bronchial tubes. These are the tubes that carry air to and from your lungs. People who have bronchitis often have a persistent cough that brings up thickened, discoloured mucus. They may also experience wheezing, chest pain, and shortness of breath. Many people who have chronic bronchitis eventually develop emphysema, which is a type of lung disease.
Chronic bronchitis is a more serious condition that develops over time rather than striking suddenly.
Bronchitis may be either acute or chronic. Acute bronchitis develops from a cold or other respiratory infection and often improves within a few days without lasting effects. Inflammation of the lining of bronchial tubes, which carry air to and from the lungs.
Emphysema is a lung condition that causes shortness of breath. In people with emphysema, the air sacs in the lungs are damaged. Over time, the inner walls of the air sacs weaken and rupture creating larger air spaces instead of many small ones. This reduces the surface area of the lungs and, in turn, the amount of oxygen that reaches your bloodstream.
When you exhale, the damaged alveoli don't work properly, and the old air becomes trapped, leaving no room for fresh, oxygen-rich air to enter. Most people with emphysema also have chronic bronchitis.
Emphysema and chronic bronchitis are two conditions that make up chronic obstructive pulmonary disease (COPD). Smoking is the leading cause of COPD. Treatment may slow the progression of COPD, but it can't reverse the damage.
3. Cystic fibrosis:
Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. These secreted fluids are normally thin and slippery. But in people with cystic fibrosis, a defective gene causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas. The slippery nature of the mucus is provided by the presence of a protein called as Cystic Fibrosis Transmembrane Conductance regulator(CFTR). This protein is activated by the Cystic Fibrosis Transmembrane Conductance regulator Gene. Thus when the CFTR gene undergoes mutation it causes Malfunction in the CFTR protein which ultimately leads to the Cystic fibrosis.
Lung Diseases Affecting the Alveoli (Air Sacs)
1. Pneumonia:
Pneumonia (Fluid fill in the Alveoli) is an infection of the lungs usually by bacteria, Infection that inflames air sacs in one or both lungs, which may fill with fluid.
What Causes Pneumonia?
· Bacteria
· Viruses
· Mycoplasmas
· Other infectious agents, such as fungi
2. Tuberculosis:
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the disease.
3. Lung cancer:
Lung cancer is a type of cancer that begins in the lungs and the uncontrolled growth of abnormal cells in one or both lungs. Your lungs are two spongy organs in your chest that take in oxygen when you inhale and release carbon dioxide when you exhale. Once the tumours have become larger and increased in number, they make it difficult for the lungs to provide oxygen to the bloodstream. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. The risk of lung cancer increases with the length of time and the number of cigarettes you've smoked. These cells usually line the air passages and divide rapidly to form tumours.
What causes lung cancer?
While most of us associate lung cancer with smoking, there are many cases of this cancer in people who’ve never smoked in their lives. And although most lung cancers – 80 percent, according to the American Cancer Society – appear in those who smoke or have smoked in their lifetime, there are other things that can cause this disease, including
· Prolonged exposure to second-hand smoke
· Exposure to radon gas in the home
· Pollution in the air, both indoor and outdoor
· Genetics
· Asbestos or diesel exhaust
Lung Diseases Affecting the Interstitium
Interstitial lung disease: A broad collection of lung conditions affecting the interstitium. Sarcoidosis, idiopathic pulmonary fibrosis, and autoimmune disease are among the many types of Interstitial lung disease.
Lung Diseases Affecting Blood Vessels
Blood coagulation ordinarily in a profound leg vein, profound vein thrombosis severs, goes to the heart, and is pumped into the lungs. The clot stops in an aspiratory corridor, frequently causing shortness of breath and low blood oxygen levels.
Different conditions can prompt hypertension in the pneumonic conduits. This can cause shortness of breath and chest torment. At the point when no reason is recognized, the condition is called idiopathic pulmonary arterial hypertension.